Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, PA, United States of America.
Department of Biomedical Engineering, Drexel University, Philadelphia, PA, United States of America.
Bone. 2021 Jun;147:115908. doi: 10.1016/j.bone.2021.115908. Epub 2021 Mar 11.
The periosteal and endosteal surfaces of mature bone are densely innervated by sensory nerves expressing TrkA, the high-affinity receptor for nerve growth factor (NGF). In previous work, we demonstrated that administration of exogenous NGF significantly increased load-induced bone formation through the activation of Wnt signaling. However, the translational potential of NGF is limited by the induction of substantial mechanical and thermal hyperalgesia in mice and humans. Here, we tested the effect of gambogic amide (GA), a recently identified robust small molecule agonist for TrkA, on hyperalgesia and load-induced bone formation. Behavioral analysis was used to assess pain up to one week after axial forelimb compression. Contrary to our expectations, GA treatment was not associated with diminished use of the loaded forelimb or sensitivity to thermal stimulus. Furthermore, dynamic histomorphometry revealed a significant increase in relative periosteal bone formation rate as compared to vehicle treatment. Additionally, we found that GA treatment was associated with an increase in the number of osteoblasts per bone surface in loaded limbs as well as a significant increase in the fold change of Ngf, Wnt7b, and Axin2 mRNA expression as compared to vehicle (control). To test the effect of GA on osteoblasts directly, we cultured MC3T3-E1 cells for up to 21 days in osteogenic differentiation media containing NGF, GA, or vehicle (control). Media containing GA induced the significant upregulation of the osteoblastic differentiation markers Runx2, Bglap2, and Sp7 in a dose-dependent manner, whereas treatment with NGF was not associated with any significant increases in these markers. Furthermore, consistent with our in vivo findings, we observed that administration of 50 nM of GA upregulated expression of Ngf at both Day 3 and Day 7. However, cells treated with the highest dose of GA (500 nM) had significantly increased apoptosis and impaired cell proliferation. In conclusion, our study indicates GA may be useful for augmenting skeletal adaptation to mechanical forces without inducing hyperalgesia.
成熟骨的骨膜和骨内膜表面被表达 TrkA 的感觉神经密集支配,TrkA 是神经生长因子(NGF)的高亲和力受体。在之前的工作中,我们证明了外源性 NGF 的给药通过激活 Wnt 信号显著增加了负荷诱导的骨形成。然而,NGF 的转化潜力受到在小鼠和人类中诱导大量机械和热痛觉过敏的限制。在这里,我们测试了 Gambogic amide(GA)的作用,GA 是最近确定的 TrkA 的强效小分子激动剂,对痛觉过敏和负荷诱导的骨形成的影响。行为分析用于评估轴向前肢压缩后一周内的疼痛。与我们的预期相反,GA 治疗与使用加载前肢或对热刺激的敏感性降低无关。此外,动态组织形态计量学显示,与载体处理相比,相对骨膜骨形成率显著增加。此外,我们发现,与载体(对照)相比,GA 处理与加载肢体中每个骨表面的成骨细胞数量增加以及 Ngf、Wnt7b 和 Axin2 mRNA 表达的倍数变化增加有关。为了直接测试 GA 对成骨细胞的影响,我们将 MC3T3-E1 细胞在含有 NGF、GA 或载体(对照)的成骨分化培养基中培养长达 21 天。含有 GA 的培养基以剂量依赖性方式诱导成骨细胞分化标志物 Runx2、Bglap2 和 Sp7 的显著上调,而用 NGF 处理则不会导致这些标志物的任何显著增加。此外,与我们的体内发现一致,我们观察到给予 50 nM 的 GA 可在第 3 天和第 7 天上调 Ngf 的表达。然而,用最高剂量的 GA(500 nM)处理的细胞凋亡显著增加,细胞增殖受损。总之,我们的研究表明,GA 可能有助于增强骨骼对机械力的适应,而不会引起痛觉过敏。